Cantor Fitzgerald Ireland Corporate Finance (“Cantor”) has a long track record in supporting Irish small and medium sized enterprises (SME’s) through raising growth capital. BioAtlantis Limited (“BioAtlantis”) is the latest such example, having been recently engaged by the company to raise funding through the Employment and Investment Incentive Scheme.
BioAtlantis is a biotechnology company headquartered in Tralee, Co Kerry with sales offices in the key trading regions including, USA, Mexico, Brazil, China and India. The Company was established in 2004, and following the initial R&D phase it commenced production in 2006. BioAtlantis entered the Biostimulant market in 2007 with its first plant strengthener product. In 2015 it commenced development of a purpose built facility at its premises in Tralee. Following capital investment of €13.5 million, the production plant was commissioned in 2019. The company is led by CEO and Founder John T. O’Sullivan. Prior to establishing BioAtlantis, John held the position of Operations Manager over the €150 million turnover Proteins Division of Kerry Ingredients.
The company produces biostimulants to protect crops from abiotic stresses, resulting in yield increases for the grower. These are made primarily from seaweed extracts. In addition BioAtlantis is in the process of developing solutions in the area of feed additives for pig and poultry health and also human nutraceuticals targeting autoimmunity and metabolic diseases.
The plant biostimulant market consists of amino and humic acids, microbials and seaweed extracts. They are applied on crops by foliar or fertigation which strengthen the crop against abiotic stresses, increase fertiliser uptake and improve yield and quality. There is a shift towards sustainability and a move towards preventative treatments to strengthen the crop so that it’s in a better position to defend itself against diseases. There is also a shift in consumer preference towards organic produce and this has been met with increased emphasis on organic agriculture by growers. These market changes has led to additional demand for alternative farming methods such as the application of biostimulants to help crops reach their genetic potential. The global market for biostimulants is forecasted to experience significant growth over the next five years in line with the push towards sustainable agriculture practices. BioAtlantis will use the new capital raised to expedite expansion into new products and markets to take advantage of the anticipated growth and market demand.